{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:04:10Z","timestamp":1789391050866,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.cld.2007.06.009","type":"journal-article","created":{"date-parts":[[2007,8,27]],"date-time":"2007-08-27T11:10:10Z","timestamp":1188213010000},"page":"549-561","source":"Crossref","is-referenced-by-count":47,"title":["Hepatotoxicity Due to Antibiotics"],"prefix":"10.1016","volume":"11","author":[{"given":"Julie E.","family":"Polson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2007.06.009_bib1","series-title":"Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver","author":"Zimmerman","year":"1999"},{"key":"10.1016\/j.cld.2007.06.009_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14740338.5.2.231","article-title":"Adverse reactions to first-line antituberculous drugs","volume":"5","author":"Forget","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cld.2007.06.009_bib3","unstructured":"Temple RJ. Hepatotoxicity through the years: impact on the FDA. Available at: http:\/\/www.fda.gov\/cder\/livertox\/Presentations\/im1389\/sld002.htm. Accessed April 9, 2007."},{"key":"10.1016\/j.cld.2007.06.009_bib4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/bmj.319.7224.1541","article-title":"Accuracy of hepatic adverse drug reaction reporting in one English health region","volume":"319","author":"Aithal","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.cld.2007.06.009_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-004-0888-z","article-title":"Incidence of drug-induced liver injury in medical inpatients","volume":"61","author":"Meier","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cld.2007.06.009_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.06.009_bib7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","article-title":"Drug-induced liver injury in a Swedish University hospital outpatient hepatology clinic","volume":"24","author":"De Valle","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2007.06.009_bib8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"issue":"9 Suppl","key":"10.1016\/j.cld.2007.06.009_bib9","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.14309\/00000434-200609001-00375","article-title":"Drug Induced Liver Injury Network (DILIN) prospective study: initial results","volume":"101","author":"Chalasani","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.06.009_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0168-8278(85)80780-7","article-title":"Drugs and the ageing liver","volume":"1","author":"James","year":"1985","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2007.06.009_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-2002-30101","article-title":"Epidemiology and individual susceptibility to adverse drug reactions affecting the liver","volume":"22","author":"Larrey","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2007.06.009_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0168-8278(92)90029-O","article-title":"Liver damage from flucloxacillin, cloxacillin, and dicloxacillin","volume":"15","author":"Olsson","year":"1992","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2007.06.009_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severs drug-induced liver disease","volume":"42","author":"Bjornsson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.06.009_bib14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/ajrccm\/145.2_Pt_1.494","article-title":"Isoniazid associated hepatitis deaths: a review of available information","volume":"145","author":"Snider","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cld.2007.06.009_bib15","first-page":"1531","article-title":"Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure","volume":"50","author":"Ohmori","year":"2003","journal-title":"Hepatogastroenterology"},{"issue":"Part 2 Suppl","key":"10.1016\/j.cld.2007.06.009_bib16","first-page":"454A","article-title":"Identification of drug-induced liver injury among 307 cases of severe liver injury: a retrospective multi-center study","volume":"34","author":"Ostapowicz","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.06.009_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1572-0241.2006.01019.x","article-title":"Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?","volume":"102","author":"Vuppalanchi","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.06.009_bib18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculous drug-induced hepatitis","volume":"35","author":"Huang","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.06.009_bib19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/archinte.1996.00440110099013","article-title":"Risk f acute liver injury associated with the combination of amoxicillin and clavulanic acid","volume":"156","author":"Rodriguez","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cld.2007.06.009_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0168-8278(95)80262-2","article-title":"Liver injury related to amoxicillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations","volume":"22","author":"Hautekeete","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2007.06.009_bib21","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s10620-005-2938-5","article-title":"Acute liver failure due to amoxicillin and amoxicillin\/clavulanate","volume":"50","author":"Fontana","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2007.06.009_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gut.47.5.717","article-title":"Co-amoxiclav jaundice: clinical and histological features and HLA class II associations","volume":"47","author":"O'Donohue","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cld.2007.06.009_bib23","first-page":"139","article-title":"Amoxicillin-clavulinic acid therapy may be associated with severe side effects: review of the literature","volume":"6","author":"Gresser","year":"2001","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.cld.2007.06.009_bib24","series-title":"Drug induced liver disease","first-page":"471","article-title":"Antibacterial and antifungal agents","author":"Westphal","year":"2003"},{"key":"10.1016\/j.cld.2007.06.009_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0168-8278(05)80476-3","article-title":"Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis","volume":"20","author":"Davies","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2007.06.009_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00008571-199508000-00011","article-title":"A slow acetylator genotype is a risk factor for sulfonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Wokenstein","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cld.2007.06.009_bib27","first-page":"25","article-title":"N-acetylation pharmacogenetics","volume":"37","author":"Weber","year":"1985","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.cld.2007.06.009_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2165\/00002018-199411030-00005","article-title":"Mechanisms of unpredictable adverse drug reactions","volume":"11","author":"Rieder","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.cld.2007.06.009_bib29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/infdis\/119.3.300","article-title":"Hepatotoxicity of erythromycin","volume":"119","author":"Braun","year":"1969","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cld.2007.06.009_bib30","first-page":"600","article-title":"Erythromycin-associated cholestatic hepatitis","volume":"158","author":"Derby","year":"1993","journal-title":"Med J\u00a0Aust"},{"key":"10.1016\/j.cld.2007.06.009_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0041-008X(75)90190-8","article-title":"Liver cell culture toxicity and surfactant potency of erythromycin derivatives","volume":"32","author":"Dujovne","year":"1975","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cld.2007.06.009_bib32","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1016\/0006-2952(84)90029-7","article-title":"Effects of erythromycin derivatives on cultured rat hepatocytes","volume":"33","author":"Villa","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cld.2007.06.009_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.7326\/0003-4819-144-6-200503210-00121","article-title":"Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review","volume":"144","author":"Clay","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2007.06.009_bib34","first-page":"891","article-title":"Long-term hepatic memory for hypersensitivity to nitrofurantoin","volume":"87","author":"Paiva","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.06.009_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/hep.1840080327","article-title":"Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases","volume":"8","author":"Stricker","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.06.009_bib36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00019048-199912000-00008","article-title":"Fluoroquinolone antibiotics: adverse effects and safety profile","volume":"8","author":"Dembry","year":"1999","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.cld.2007.06.009_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0168-8278(86)80495-0","article-title":"Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases","volume":"3","author":"Stricker","year":"1986","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2007.06.009_bib38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin: a meta-analysis","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.cld.2007.06.009_bib39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-75-4-643","article-title":"Isoniazid and liver disease","volume":"75","author":"Brummer","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2007.06.009_bib40","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cld.2007.06.009_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/01926230252824699","article-title":"Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity","volume":"30","author":"Williams","year":"2002","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.cld.2007.06.009_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-2008-1040725","article-title":"Isoniazid-induced liver disease","volume":"1","author":"Maddrey","year":"1981","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cld.2007.06.009_bib43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculous drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.cld.2007.06.009_bib44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cpt197518170","article-title":"Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites","volume":"18","author":"Mitchell","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cld.2007.06.009_bib45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00004836-198109000-00012","article-title":"Risk factors for isoniazid induced liver dysfunction","volume":"3","author":"Dickinson","year":"1981","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.cld.2007.06.009_bib46","first-page":"58","article-title":"Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis","volume":"129","author":"Gurumurthy","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cld.2007.06.009_bib47","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","article-title":"Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis","volume":"37","author":"Huang","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.06.009_bib48","first-page":"1072","article-title":"Rifampin-induced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin","volume":"133","author":"Sarma","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cld.2007.06.009_bib49","first-page":"151","article-title":"Isoniazid hepatitis among pregnant and postpartum Hispanic patients","volume":"104","author":"Franks","year":"1989","journal-title":"Public Health Rep"},{"key":"10.1016\/j.cld.2007.06.009_bib50","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/gast.2002.36591","article-title":"The human bile salt export pump: characterization of substrate specificity and identification of inhibitors","volume":"123","author":"Byrne","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2007.06.009_bib51","series-title":"Side effect of drugs. Volume 4","author":"Meyer","year":"1964"},{"key":"10.1016\/j.cld.2007.06.009_bib52","first-page":"733","article-title":"Centers for Disease Control and Prevention, American Thoracic Society. Update: fatal and\u00a0severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cld.2007.06.009_bib53","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00004836-199706000-00019","article-title":"Pyrazinamide-induced granulomatous hepatitis","volume":"24","author":"Knobel","year":"1997","journal-title":"J\u00a0Clin Gastroenterol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T04:30:22Z","timestamp":1587875422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326107000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S1089326107000530"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2007.06.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}